raloxifene hydrochloride has been researched along with Hyperlipemia in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Domeki, N; Ikeda, S; Kasai, K; Kawagoe, Y; Matsumura, M; Monden, T; Nakatani, Y; Shimizu, H; Yanagi, K | 1 |
| Nakamura, T; Sakai, A | 1 |
| Jneid, H; Shepard, DR; Thacker, HL | 1 |
| Geiger, MJ; Wenger, NK | 1 |
| Okazaki, R | 1 |
| Mamounas, EP | 1 |
4 review(s) available for raloxifene hydrochloride and Hyperlipemia
| Article | Year |
|---|---|
[Effects of SERMs on bone health. Efficacy of SERM for incidence of fractures in osteoporotic patients with lifestyle-related diseases].
Topics: Adiponectin; beta Catenin; Diabetes Mellitus, Type 2; Female; Fractures, Spontaneous; Humans; Hyperlipidemias; Hypertension; Life Style; Meta-Analysis as Topic; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Signal Transduction; Spinal Fractures; Wnt Proteins | 2010 |
Gender, hyperlipidemia, and coronary artery disease.
Topics: Adult; Aged; Cardiotonic Agents; Coronary Artery Disease; Estrogen Replacement Therapy; Female; Health Behavior; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Life Style; Male; Middle Aged; Primary Prevention; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Sex Factors | 2003 |
[Effects of SERM on the cardiovascular system].
Topics: Arteriosclerosis; Cardiovascular Diseases; Clinical Trials as Topic; Female; Humans; Hyperlipidemias; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Stroke | 2007 |
Breast cancer chemoprevention.
Topics: Adult; Aged; Aged, 80 and over; Animals; Anticarcinogenic Agents; Breast Neoplasms; Carcinoma; Clinical Trials as Topic; Double-Blind Method; Endometrial Neoplasms; Estrogen Antagonists; Europe; Female; Humans; Hyperlipidemias; Hysterectomy; Mammary Neoplasms, Experimental; Menopause; Mice; Mice, Nude; Middle Aged; Neoplasms, Second Primary; Neoplastic Syndromes, Hereditary; Osteoporosis; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Risk Factors; Tamoxifen; United States | 2000 |
2 other study(ies) available for raloxifene hydrochloride and Hyperlipemia
| Article | Year |
|---|---|
Effect of raloxifene on serum lipids for type 2 diabetic menopausal women with or without statin treatment.
Topics: Aged; Bone Density Conservation Agents; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Menopause; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride | 2010 |
Baseline characteristics of menopausal women with coronary heart disease in cardiovascular outcomes clinical trials of menopausal hormone therapy or raloxifene.
Topics: Aged; Anticholesteremic Agents; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus; Estrogen Replacement Therapy; Female; Humans; Hyperlipidemias; Lipids; Menopause; Middle Aged; Patient Selection; Raloxifene Hydrochloride; Risk Factors; Smoking | 2005 |